INHC vs. RENX, COG, FDBK, IQAI, TRLS, DVRG, SENS, EMIS, CRW, and INS
Should you be buying Induction Healthcare Group stock or one of its competitors? The main competitors of Induction Healthcare Group include Renalytix (RENX), Cambridge Cognition (COG), Feedback (FDBK), IQ-AI (IQAI), Trellus Health (TRLS), DeepVerge (DVRG), Sensyne Health (SENS), EMIS Group (EMIS), Craneware (CRW), and Instem (INS). These companies are all part of the "health information services" industry.
Induction Healthcare Group (LON:INHC) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.
Induction Healthcare Group has higher revenue and earnings than Renalytix. Induction Healthcare Group is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.
Renalytix has a net margin of 0.00% compared to Induction Healthcare Group's net margin of -120.26%. Induction Healthcare Group's return on equity of -47.42% beat Renalytix's return on equity.
42.4% of Induction Healthcare Group shares are held by institutional investors. Comparatively, 31.0% of Renalytix shares are held by institutional investors. 46.7% of Induction Healthcare Group shares are held by company insiders. Comparatively, 35.7% of Renalytix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Induction Healthcare Group had 4 more articles in the media than Renalytix. MarketBeat recorded 4 mentions for Induction Healthcare Group and 0 mentions for Renalytix. Induction Healthcare Group's average media sentiment score of 0.25 beat Renalytix's score of 0.00 indicating that Induction Healthcare Group is being referred to more favorably in the media.
Renalytix received 9 more outperform votes than Induction Healthcare Group when rated by MarketBeat users. However, 93.33% of users gave Induction Healthcare Group an outperform vote while only 74.19% of users gave Renalytix an outperform vote.
Induction Healthcare Group has a beta of -0.38, indicating that its stock price is 138% less volatile than the S&P 500. Comparatively, Renalytix has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500.
Summary
Induction Healthcare Group beats Renalytix on 10 of the 15 factors compared between the two stocks.
Get Induction Healthcare Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for INHC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Induction Healthcare Group Competitors List
Related Companies and Tools
